Received May 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | U7947AA | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | 2088619 | OT |
No adverse event; HBP reported patient was administered ROTATEQ & VAXELIS during a temperature excursion. Date of administration was 04/28/2025. No additional details reported. No additional AE reported. No PQC reported. ? Names of vaccines involved (including; This spontaneous report was received from a Health business professional and refers to a identified patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 28-APR-2025, the patient received a dose of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus (VAXELIS), Injection (lot #U7947AA, expiration date: 31-Oct-2026) 0.5 mL (1 dose), and a dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), (lot #2088619, expiration date: 09-Mar-2026) both for prophylaxis, during a temperature excursion of 0°C during 1hour. There were no previous temperature excursions. No additional details reported. No additional AE reported. No PQC reported.; Reporter's Comments: